Novo Nordisk’s CagriSema for Obesity and Type 2 Diabetes Shows Superior Results in REDEFINE 2 Trial
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
